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Abstract
Currently chemotherapy and radiotherapy are the most popular methods for cancer
treatments after surgery, but lack of specificity and are thus toxic to the healthy human cells.
Studies have shown that targeted therapies have been linked to activation of apoptosis signal
pathways (cascade of caspases) in cancer cells including intrinsic and extrinsic pathways. One
of the major pathways leading to caspase activation involves the release of cytochrome-c from
mitochondria. However, in some tumor cells this pathway is inactivated due to the mutation of
mitochondria membrane stabilizing proteins (e.g. Bcl-2, Bcl-xL). Therefore, the overall objective
of this proposal was to understand the mechanism and the kinetic of cytochrome-c release from
the mitochondria, so novel and improved molecular target therapies can be developed against
cancers. For this purpose, we have successfully constructed a cytochrome C-GFP reporter cell
line using human lung cancer cells. The result from western blot confirmed the presence of the
intact cytochrome C-GFP fusion protein in the reporter cell line. We investigated the release
kinetics of cytochrome C-GFP in response to three different apoptosis-inducing reagents;
TRAIL, Staurosporine, and Tarceva. The result from this study illustrated that the dynamic
release of cytochrome C-GFP is dependent on the cell types and doses. We have also developed a
system to investigate the anti-cancer drugs response in a sequence of time interval, Microfluidic
Duration Device. The microfluidic duration device with the reporter cell line can be further used
for preclinical study in the development of combination agents for target therapy.
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1. Introduction:
Cancer is one of the principal causes of death in the adult population. Currently, noninvasive treatment for cancer is chemotherapy. In the last three decades, survival of cancer has
been significantly improved by chemotherapy. However the success of cancer chemotherapy is
still severely limited by the lack of selectivity of anti-cancer drugs to malignant cells leading to
dose-limiting toxicity and the resistance of cancer cells to the conventional anti-cancer drugs.
Therefore, with better understanding of molecular signaling pathway that linked to activation the
apoptosis in cancer cell line, we can develop a novel target therapy that show more efficiency,
good tolerability and less resistance profiles. By developing a reporter cell lines using human
cancer cells, we can the study of anti-cancer drug mechanisms systematically in cell death
pathways. It may facilitate the development of molecular target therapy for cancer.

1.1 Apoptosis
Apoptosis, or programmed cell death (PCD), is involved in numerous cell processes
including cell development, elimination of damaged cells and maintenance of cell homeostasis.
During apoptosis, various biochemical events occur inside the cell, which lead to morphological
changes such as loss of cell membrane attachment, cell shrinkage, nuclear fragmentation,
chromatin condensation, and chromosomal DNA fragmentation [1]. These events are carried out
by intracellular protease enzymes called caspases that destroy a large set of cellular proteins
important for cell viability. Two well known pathways that activate the caspase cascade are: a.
the extrinsic or receptor mediated-pathway and b. the intrinsic or mitochondrial pathway.
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1.1.1 Extrinsic Pathway
The extrinsic pathway triggers apoptosis independently of p53gene, in response to proapoptotic ligands (e.g. tumor necrosis factor (TNF)-related apoptosis-inducing ligand or Apo2
ligand as illustrated in Figure 1) [2,3]. These ligands activate specific pro-apoptotic receptors,
known as death receptors (DR4 and DR5). The activation of death receptors (DR4 and DR5)
then leads to the recruitment of the adaptor Fas associated death domain (FADD). FADD then
activates procaspases 8 and 10 which in turn form the death-inducing signaling complex (DISC).
As a result, self-cleavage of procaspase-8 results in the activation caspase-8 [4, 5 ]. Caspase-8
then cleaves procaspase-3 and -7 into caspase-3 and -7, which in turn trigger apoptosis. In a
situation where there are insufficient quantities of caspase-8, -3, and -7, for the induction of
apoptosis, the intrinsic pathway (see below) is activated through cleavage of BH3. Interactive
domain death agonist (BID) leads to the formation of truncated BID (tBID) by casapse-8, which
allows the apoptosis signal to be amplified [6, 9].

Figure 1. The extrinsic apoptotic pathway; Solid lines in the Figure correspond to the protein that is acting
upon another molecule and dashed lines represent a cleavage event that is changing inactive form of protein
to active form[9]
2

1.1.2 Intrinsic pathway
The intrinsic pathway is dependent of p53 gene that is known as tumor-suppressor gene.
DNA damage and other types of severe cell stresses trigger the p53 genes, as illustrated in Figure
2 [6, 9]. In this pathway, mitochondria play an important role in the regulation of cell death and
cell survival: mitochondrial function is regulated by the BCL-family, which in turn regulates the
release of protein from the space between the mitochondrial inner and outer membrane. Once the
proteins are released in the cytosol it activates caspase proteases which lead to cell death [7].
The BCL-family is divided in two subgroups, pro-death (proapoptotic) members and anti-death
(anti-apoptotic) members [10, 11, 12] Bak and Bax are prodeath members that have been
categorized as the last gateway of cytochrome c release, and their homooligomerization on the
mitochondrial membrane is essential for release [8]. The anti-death members of Bcl-2 family
such as, Bcl-XL and McL-1 prevent mitochondrial protein release by interacting with and
inhibiting both Bak/Bax and BH3-only proteins [8, 13].
Upon a stimulus, the proapoptotic protein such as Bax undergoes conformational changes
to form oligomers and translocates itself to mitochondria. Translocation of Bax to mitochondria
leads to the release of cytochrome c [14, 15]. Once cytochrome c is released it interacts with the
C-terminal WD40 repeats of Apaf-1 and is induced into a huge complex, known as an
apoptosome. The formation of apopotosome leads to activation of the initiator caspase-9 [11,
16]. Upon the activation of caspase-9 initiates the executioner caspases including caspase-3,-6,
and -7, and consequently leading to cell apoptosis. On the other hand, the anti-apoptotic
members of the BCL2 family, e.g. BCL2, BCLXL, and MCL1, regulate the mitochondriainitiated caspase activation pathway by preventing the release of cytochrome c in the presence of
apoptotic stimuli [17]. Deregulation in apoptosis signaling pathways may cause diseases, such as
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cancers, immune diseases, and neurodegenerative disorders. In the last four decades, over 2
million papers have been published by researchers in regards to finding a cure for cancer.

Figure 2. The intrinsic apoptotic pathway; Solid lines in the Figure correspond to the proteins that are acting
upon another molecule and dashed lines represent a cleavage event that is changing inactive form of protein
to active form[9].

1.2 Cancer
In general, there is a cell cycle regulation of cell production in order to keep the number
of any particular cell type constant. However when there is deregulation in the cell cycle it gives
rise to clones of cells that develop into a tumor. Tumor is divided into two categories, cancerous
(malignant) or noncancerous (benign). A malignant tumor penetrates the surround normal tissues
and also tends to metastasize to invade distant organs. According to the American Cancer Society
in 2012, the estimated amount of death due to cancer is 577,190 up by 14% from 2009 [18].
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1.2.1 General cancer treatment
Current methods to treat cancer include conventional therapy such as chemotherapy,
radiotherapy, vaccine, gene therapy and immunotherapy. Surgery is the original and still remains
as the major therapeutic measure for tumors at earlier stages. One of the main disadvantages of
surgical treatment is that not all the tumor is removed through this process, not to mention the
added general risks that go along with surgery (such as that of death in the removal of brain
tumor). Radiotherapy involves using high energy radiation to locally eradicate cancerous cells
while sparing normal ones. It is mainly used, in combination with surgery and/or chemotherapy,
for non-metastatic or recurrent cancer treatment [19]. It is often used prior to surgery to reduce
the size of a tumor, or after surgery to destroy any remaining cancer cells, and to relieve
symptoms. However, the lack of specificity renders the procedure potentially toxic, as evidenced
by it demonstrating the most discernible side effect due to its indifferent targeting of both
cancerous and noncancerous cells.

1.2.2 Target Therapy
A new approach is to develop molecular target drugs to cure cancer. The main goal of
targeted cancer therapies is to eliminate malignant cells without causing harm to the normal
healthy cells. Many of these therapies focus on proteins that are involved in cell signaling
pathways, which form a complex communication system that governs basic cellular functions
and activities, such as cell division, cell movement, cellular response to specific external stimuli,
and even cell death. By blocking the signals that tell cancer cells to grow and divide
uncontrollably, targeted cancer therapies can help stop cancer progression and may induce
cancer cell death through an apoptotic process [3]. Other targeted therapies can cause cancer cell
5

death directly, by specifically inducing apoptosis, or indirectly, by stimulating the immune
system to recognize and destroy cancer cells and/or by delivering toxic substances to them.
Studies have shown that targeted therapies have been linked to the activation of apoptosis signal
transduction pathways in cancer cells, including the aforementioned extrinsic and intrinsic
pathways [20].
1.3 Current obstacles/limitation of apoptosis detection in anti-cancer drug screening
The process of drug discovery and delivery is limited by a number of challenges. One of
the main challenges is the analysis of drug in cellular environment in a more accurate and rapid
manner. Current conventional techniques for delivering time varying stimuli are not compatible.
It requires carefully timed pipetting and multiple rinse steps to completely remove stimuli in
mid-experiment. Perfusion culture systems have been used to overcome many of these obstacles
by replenishing culture medium continuously; however most continuous-flow chambers
accommodate only one experimental condition at a time, and as a result, they also limit
throughput [21]. This need leads to the development of microfluidic devices. The microfluidic
devices have been used for pre-clinical and clinical studies. They are very useful tools for target
selection which can help in the manufacturing of new therapeutic product. These devices can
address the inherent complexity of cellular systems with massive experimental parallelization
and 4D (multiparameter outputs plus time) analysis and sorting of single cells [22]. One main
advantage of utilizing this technology is that it requires low number of cell numbers, smaller
reagent volumes. These devices are in microscale (µm) units that provide fast mass transfer
kinetics, shorter reaction time and the possibility of parallel operation that provides the unique
ability to monitor single-cell signaling dynamics [22, 23].
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In the microscale environment fluids exhibit unique characteristics dominated by laminar
ﬂow, diffusion, ﬂuidic resistance, surface area to volume ratio, and surface tension. The flow
behavior is usually characterized by Reynolds number, given by the equation:

=

/

(where F is the density, U is the average velocity of the flow, D is the equivalent hydraulic
diameter of the microchannel, and µ is the fluid viscosity) [22, 23]. For most of the microfluidic
system, the Reynolds number is limited to <100. The fluid flow under this condition is laminar
with no inertia and allows the solute transport dominated by local diffusion [24]. These
properties greatly enable accurate delivery of drugs, both spatially and temporally, and can help
to study the cellular responses, static or kinetic, to novel targeted anticancer agents and
pharmacological compounds. Increasing number of reports provide innovative solutions that
reach beyond simple proof-of-principle studies to applications of microfluidics in drug discovery
and

clinical

diagnostics

[22].

1.4 Microfluidic Duration Device
In the present study, we are using the “Microfluidic Duration Device” system to study the
dynamic release of cytochrome c in human lung cancer cell line under the stimulation of
anticancer agents. The idea of the device originally stems from the “Microfluidic flow-encoded
switching device” network system described in [21]. The purpose of this device is to control the
inlet flow ratio in time. The state of the network can be controlled dynamically, and cells
throughout the network can be exposed to different stimulus regimens [21, 22]. As a result it will
7

provide a dynamic profile of cellular response to a stimulus (e.g., an anticancer drug). To
demonstrate this approach, we will used our constructed PC-9 with cytochrome C-GFP cell line
in the microfluidic duration device and stimulate with TRAIL to monitor the dynamic release of
cytochrome C in real-time image by controlling the duration of drug delivery. For the future
purposes, we can use this device with multiple drugs in a time interval-sequence that would help
derive the optimal time window within which there is a synergistic drug response. For instance,
these results can further improve target therapy in cancer treatment by suggesting different
designs or implementations of the drugs within pharmaceutical devices that allow them to be
administered based on their optimal time of effect.
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2. Objective of this study
The main goal of cancer target therapy is to kill tumor cells without causing harm to
normal cells. Target therapy is mainly focus on proteins that are involved in cell signaling
pathways, which form a complex communication system that governs basic cellular functions
and activities. Studies have shown that intrinsic pathway is one of the major pathways that
involve caspase activation. Importantly, caspase activation is triggered by the release of a proapoptotic protein known as cytochrome c. However, the mechanism and kinetics of cytochromec release under multiple stimuli is still questionable in different mammalian cancer cell line. The
first aim of this project was to develop a human lung cancer reporter cell line, which contains
cytochrome c-GFP fusion protein and monitor the real time response of anti-cancer drug. For this
purpose, stable transfected human lung cancer cell line was constructed via the electroporation
method. To study the apoptotic response of different drugs, the following apoptosis-inducing
agents were investigated: TRAIL (TNF- Related Apoptosis Inducing Ligand), Staurosporine,
Tarceva. According to the hypothesis, TRAIL and staurosporine should have different releasing
time of cytochrome c as prior studies have shown that TRAIL induces apoptosis via extrinsic
pathway while staurosporine induces apoptosis by release of cytochrome c via intrinsic pathway.
TRAIL and staurosporine can be used as controls to study the natural product (Actein) to
investigate if this natural product has a potential to induce apoptosis in human lung cancer cell,
and if it does then what signaling pathway it triggers for apoptosis. We compared the releasing
time of cytochrome c after induction of TRAIL, Staurosporine and Tarceva. The second aim of
this project was to combine the reporter cell line with “Microfluidic Duration Device” to study
the stimulus response in time series data from the cells.
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3. Materials and Methods
3.1 Cytochrome-c GFP plasmid amplification and DNA Isolation
DH5-α bacterial strain was transformed with the pCytochrome C-GFP as shown in
figure 3, requested from Douglas R. Green Lab, which contained cytochrome C gene inframe fused with green fluorescent protein (GFP) gene [25]. Bacterial colonies containing the
plasmid were separately amplified in 500 ml Lysogeny broth (LB medium) for 24 hours.
After the amplification, DNA isolation was performed using the QIAGEN plasmid Maxi

Mouse cytochrome C

prep kit and the DNA concentration was determined using spectrophotometer.

Figure 3: Mouse cytochrome-c gene was ligated
into pEGFP-N1 vector at Xhol and BamHI sites
and GFP is on the c-terminal.

3.2 Construction of reporter human lung cancer cell line
Cell culture: Human lung cancer cells (PC-9) were culture in RPMI 1640 ( ATCC,
Manasssas, VA) media supplemented with 10% heat inactivated fetal bovine serum (FBS,
Atlanta Biologicals) and 1% penicillin (100 U/ml), streptomycin (100 mg/ml) (P/S; Gibco,
Invitrogen) at 37oC in a 5% CO2 in T75 flask.
Stable Transfection: For the construction of stable reporter cell line containing cytochrome CGFP fusion protein, we used electroporation method. Adherent cells were trypsinized
10

and centrifuged to obtain the cell concentration of 12 x106 cell/ml. The cell suspension of 5x106
cell/ml was added to 0.4cm cuvette with 50µg of pCytochrome C-GFP in total 500µL volume.
BioRad electroporator machine was used for electroporation with an electric impulse which was
set for a 960µF capacitance and a 250V (voltage). After the impulse, the cells were immediately
transferred into the 10 cm2 with 9ml of RPMI media. After 24 hours, the cells were fed with
fresh RPMI growth medium. The expressions of fusion protein gene were analyzed through
fluorescence microscopy after 48 hours at the wavelength of the excitation maximum 488 nm;
emission maximum 507 nm. For the generation of stable cell lines, transfected PC-9 cells were
selected in the presence of 650µg/ml G e net ic i n ( G418) for 2 weeks, and clones expressing
mitochondrial cytochrome c-GFP were enriched.
FACS sorting: After the two weeks allowed for stable tranfection, cloning rings were used to
selected clones that expressed GFP signals. Those clones were sorted by fluorescence activated
cell sorter machine (FACS) at MSKCC FACS facility. The FACS machine was set up using
non-transfected PC-9 cells (as negative control cells) and stable transfected cells expressing
GFP signals. Based on the fluorescent threshold value, the cells expressing high GFP signals
were sorted. The sorted cells were cultured in a T25 flask with RPMI 1640 medium.

3.3 Characterization of the reporter cell line
To confirm whether the fluorescent tag GFP is still fused with cytochrome-c gene,
western blot analysis was performed. For cell lysis, a confluent T25 flask of stable transfected
cells were trypsinized and washed three times using 1X Phosphate buffer saline (PBS). Then
cell pellet was gently resuspended in 1X extraction buffer [protease inhibitor; 0.1 mM PMSF, 1
µg/ml leupeptin, 1 µg/ml aprotinin, 1µg/ml pepstatin], incubated in ice for 30 min and every
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10 minutes cells were vortex. The cell extracts were separated from the cell debris by
centrifugation at 16,000 g for 15 minutes at 40C. The protein content of the supernatant was
determined by the Bradford assay and samples were stored at -80oC until use.
For analysis, 40 µg of cell proteins were mixed with loading buffer, the mixture was
boiled for 5 min and subjected to 15% SDS- PAGE gel at 150 V for 1h. The gel was
electroblotted to an Immun-Blot PDVF ( Polyvinylidene diflouride ) membrane at 30 V for 16 h.
Membranes were blocked for 1 h with 3% nonfat milk in TBS-T at room temperature and then
incubated with an anticytochrome C (1:1000) and anti-EGFP (1:1000). The membrane were
rinsed three time with 1X TBS-T buffer and incubated with horseradish-peroxidase-conjugated
goat anti-mouse polyclonal antibody (1:5000) for 1h. After the secondary antibody incubation,
the membranes were rinsed with 1X TBS-T buffer and bound antibodies were detected by using
TMB solution, prepared according to the manufacture’s instruction (10 ml was added to each
membrane for 15 min until the bands showed up.)

3.4 Co-localization by Confocal Microscopy
The reporter cell line gene expression was confirmed by co-expression of cytochrome cGFP with mitochondria using 2 m M Mitotracker Red CMXRos (Molecular Probes, Invitrogen).
One day before the experiment, the reporter cells were seeded in 2 well chambers at the
concentration of 23x104cell/ml and incubated at 370C. At the day of the experiment, one well of
2-well chamber stained with 2mM of Mitotracker Red CMXRos (Molecular Probes,
Invitrogen). After 15 minutes of incubation, cells were washed with 1XPBS and 500 µl of
Serum Free Medium was added to each well. Confocal images of green cyctochrome-c GFP
were collected using 488nm excitation light from an argon laser. Images of red MitoTrackerRed
12

CMXRos fluorescence were collected using a 568-nm excitation light from argon laser. Images
were taken in z-stack for 3-D imaging analysis of the cells. A 3-D construction was done in
LEICA software. Co-localization analysis was done using Image J software.
On the same day, another set of samples were prepared, cell culture procedure was
followed as above. Prior to addition of Mitotracker Red CMRos, TRAIL at 100ng/ml was added
to the 2 well chambers and incubated for 2 hours. After incubation, cells were washed twice
with 1XPBS and then 2mM Mitotracker Red CMRos. For confocal imaging, the same
procedure was followed as above.
3.5 Monitoring the release of Cytochrome c after stimulation of anti-cancer drugs
Stable transfected PC-9 cells expressing the cytochrome-c- GFP protein were seeded into
a 12 well plate at the concentration of 0.5 x106 cell/ml per well. After 24 hours of incubation, the
cell culture medium was changed into Serum free Medium (SFM) and cells were incubated in
SFM for 2 hours. After 2 hours of incubation, different apoptosis inducing agents were added to
the reporter cell line; 100ng/ml TRAIL was added to first three wells, 400ng/ml TRAIL was
added to other three wells, 1mM Staurosporine at the other three wells. Time lapsed images
were taken using Carl Zeiss microscope at 20X objective for 12 hours at 30 minute intervals.
Similarly, another set of experiment was performed, where reporter cell were seeded into
a 12 well plate at the same concentration of 0.5 x106 cell/ml per well. After 24 hours of
incubation, cell culture medium was changed into SFM. After 2 hours of cell incubation at SFM,
400ng/ml TRAIL was added to first three wells, 200nM Tarceva was added to the next three
wells and nodrugs (control) on the three other wells. As mentioned above, time lapse images
were recorded at 20X, for duration of 12 hours at 30 minute intervals.
13

3.6 Image Analysis
For image analysis, Image-Pro software was used. All the fluorescence images were
converted to grayscale. To avoid white noise, despeckle filter was selected with following
settings: 7x7 despeckle and a sensitivity of 3. For background correction, three areas lacking in
cells from the image were selected, and the mean value of these regions used as a background
reference. This mean was subtracted from the despeckled image. this, areas of interest (AOIs)
were chosen by selecting a circle around the cells and recording the mean and standard deviation
value for each AOI. For analysis, AOIs were randomly selected with three replicates per
condition.
To measure the duration/timing of cytochrome C-GFP release Image Pro software was
used. The standard deviations of the average brightness of all the pixels in the image of userselected individual cells were measured. The standard deviation was higher when cytochrome CGFP was punctuated inside the mitochondria and low at diffusive. The total average fluorescent
intensity in single cells stayed the same as the cytochrome C-GFP was being released from
mitochondria. We normalized standard deviation, where standard derivation is divide by its
average (CV=STD/Mean). The sudden drop in normalized standard deviation (or Coefficient of
Variance) corresponds to the timing of cytochrome-c GFP release in the cells as indicated in the
quantitative analysis of time-lapse images.

3.7 Fabrication of Microfluidic Duration Device
The conceptual drawing of Microfluidic Duration Device came from King, R.K and
Sihong Wang [21]. Briefly, electronic drawings were made in AUTOCAD software. The
dimensions of the device are: diameter of the experimental channels is 400µm, two inlet
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diameters are 600 µm, and channel height is 100 µm. Manufacturing of the device was done by
the general, standard protocol of PDMS. Briefly, the PDMS elastomer devices were molded from
the masters using two-part Sylgard silicon elastomer (a mixture of 1:10 silicon elastomer and
curing agent degassed and poured against the silicon master). Once cured, each PDMS device
was punched with inlet/outlet holes, treated with oxygen plasma membrane , bonded to the glass
slide by putting both treated surfaces in contact to each other immediately.
3.8 Statistcal Analysis:
Analysis of Variance (ANOVA) was performed within nodrug (Control) to determine if there is
significant different in coefficient of variance at different time point (p<0.05). For all three
treated group with drugs we performed two-tailed paired t-test with confidence interval of 95%
to determine if there is any significant different in the distribution of GFP expression over
different time points
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4. Results
4.1 Cytochrome c-GFP reporter cell line
In this study, we used the electroporation
for the stable transfection of PC-9 cells (human
lung cancer cells) with cytochrome C-GFP
fusion protein gene. Transfected PC-9 cells
with

cytochrome

C-GFP

fusion

protein

A

B

Figure 4: (A) PC-9 cells transfected with cytochrome c
gene in-frame fused with green fluorescent protein
(GFP) gene. (B) PC-9 cells transfected with pdEGFP
plasmid (control) and images were taken with a 20X
objective under a fluorescence microscope.

expression were compared to transfected PC-9 cells with GFP expression using pd4EGFP
(control vector). Figure 4A shows that the GFP expression in cytochrome C-GFP PC-9 cells is
punctuated, but smooth in PC-9 cells transfected with the control plasmid (Figure 4B).
FACS analysis performed before sorting allows the selection of the enclosed region, P4,
as the cell population that contained high GFP signal as shown in Figure 5A. The cell population
expressing GFP signal was 14%, and 74% of that population was not expressing GFP signal.
14% of the cells with GFP expression were sorted, culture-expanded and frozen down. Figures
5B, 5C depict the total population of PC-9 and PC-9 with cytochrome C-GFP after sorting.
Figure 5D shows the fluorescence intensity of GFP signal within these two populations. The blue
line histogram in Figure 5D represents the non-transfected PC-9 (as negative control) and the red
line histogram represents the transfected PC-9 with cytochrome C-GFP. The statistical analysis
illustrated that 85% if cytochrome C-GFP cells had GFP expression in R1 region while only 7%
of control cells were in the same region.

16

(A)

(B)

(C)

Neg-

GFP

(D)

R1

Figure 5: (A) FACS analysis of PC-9 with cytochrome-c GFP before sorting, 14% of
the cell population had the recombinant cytochrome –c GFP, (B) Cell population of
PC-9 cells after sorting, (C) Cell population with GFP expression after sorting, (D)
Histogram fluorescence intensity of two population. The R1 region showed that 85% in
R1 were PC-9 cells with cytochrome-c-GFP and 7% were cells with no GFP expression
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4.2 Confirmation of localization of cytochrome c-GFP within mitochondria
Mitotracker red color fluorescent dye was used to confirm the punctuation of GFP within
mitochondria. Using a confocal microscope operated under the two-channel measurement mode,
channel 1 for Alex 488 and channel 2 for DsRed, series of images in z-direction were obtained at
40X objective (Figure 6A, 6B). Figure 6A and 6B are from the middle layer of z-direction series
of images, and the punctuation of GFP inside the mitochondria was clearly shown in Figure 6A.
The location of mitochondria was observed using DsRed filter at 568nm excitation (Figure 6B).
The overlay image demonstrated the co-localization of GFP signal inside the mitochondria
(Figure 6C).

Quantitative co-localization analysis of overlay images was determined by

Pearson's correlation coefficient using Image J software. Pearson’s correlation coefficient of
overlay image was Rp= 0.772, representing a clear correlation between the two colors; therefore,
as the intensity value increases in channel 1(ch1), the value of intensity increases in channel 2
(ch2). From the series of images in z-direction overlay a 3-D animation image of cells with
cytochrome-c GFP and mitotracker was constructed (Figure 6E).
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A

B

D
Red Channel

C

Figure 6: Colocalization of cytochrome C-GFP
with mitochondria. All the images were taken
in 40X oil objective under confocal
microscope. (A) Cytochrome C-GFP punctuate
inside the mitochondria, (B) Cells were stained
with Mitoctracker for mitochondria, (C)
Overlay image of cytochrome C-GFP with
mitotracker (D) Quantitative analysis of
colocalization image, where Rp=0.772, (E) 3-D
image of colocalization of cytochrome C-GFP
with mitochondria

Green Channel

E

4.3 Confirmation of cytochrome C-GFP fusion protein expression
A comparison of cytochrome C-GFP and cytochrome-c was obtained by western blotting. The
result from membranes with anti-cytochrome C-GFP antibody showed two prominent bands, one
between 89KDa & 36KDa and other below 18 KDa (Figure 7A). The band above 36 KDa
corresponds to the cytochrome C-GFP molecular weight (at approximately 39 KDa) and the one
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below 18KDa band corresponds to endogenous cytochrome C, (which is approximately 12 KDa),
as shown in Figure 7A. The anti-cytochrome C-GFP antibody recognizes these two bands
because the cytochrome C- GFP reporter cell line contains both the endogenous cytochrome C as
well as the cytochrome C-GFP fusion protein. A band at 39 KDa also illustrates that cytochrome
C is still fused with GFP protein. Similarly, the membrane exposed to anti-EGFP antibody also
shows a prominent band at around 39KDa confirming that GFP protein is still fused with
cytochrome C (Figure 7B). However, there was another band observed around 31 KDa, which
could correspond to the molecular weight of GFP (27KDa). In Figure 7B, there were series of
faint bands between 39KDa and 31KDa, which could be due to partial proteolytic cleavage of
cytochrome C-GFP fusion protein.

(A)

Anti-Cytochrome c
89KDa

Cytochrome c -GFP

36KDa
31KDa
18KDa

Cytochrome c

(B)

Anti-EGFP
89KDa

Cytochrome c-GFP
Partially cleaved
fusion protein

36KDa
31KDa

Figure 7: (A) Western blotting with anti-cytochrome c antibody, cytochrome C-GFP
had a band showed ~39 KDa, and cytochrome C band showed ~12KDa. (B) Western
blotting with anti-EGFP antibody, prominent band showed at 39KDa that illustrate
cytochrome C is still fused with GFP protein and near 31 KDa representation of
partial proteolytic cleavage of cytochrome C-GFP fusion protein.
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4.4 Release kinetics of cytochrome C-GFP observed in real time
The punctuated pattern of cytochrome C-GFP expression became notably diffused after
the introduction of multiple drugs (TRAIL, Staurosporine, Tarceva). The release time of
cytochrome C-GFP was monitored through time-lapse fluorescence microscopy at 488/507nm
excitation/emission. In Figure 8, where the cells were treated with TRAIL (400ng/ml), a majority
of cytochrome c GFP release was observed between 0.5 and 1 hr. The timing of cytochrome C
release is dependent on the concentration and types of anti-cancer reagents. However, it was
observed through time lapse images that different concentrations of apoptosis-inducing reagent
give different release times of cytochrome-c GFP.

A

C

B

D

Figure 8: (A-D) Sample records from
the
time
series
fluorescence
measurement of cytochrome-c GFP
on living PC-9 cells with 400ng/ml
TRAIL-induced apoptosis treatment.
Majority of initiation of cytochrome
C-GFP release was monitored
between 0.5 and 1 hr. All the images
were taken at 20x objective and Scale
bar, 50µm.

Figure 9 (A-E) represents by the normalized standard deviation, where standard derivation is
divide by its average (CV=STD/Mean). The drop in normalized standard deviation (or
Coefficient of Variance) corresponds to the cytochrome-c GFP release in the cells as indicated in
the quantitative analysis of time-lapse images. TRAIL administered at 400ng/ml initiates the
release of cytochrome C-GFP between 0.5 and 1 hr time points (Figure 9A), that at 100 ng/ml
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does so between the 2 to 3 hr time points (Figure 9B); a 1µM Staurosporine sample does so
between the 0.5 and 1hr time points (Figure 9C); and the 200mM Tarceva dose invokes the
release between the 1 and 1.5 hr time points (Figure 9D). There was no release measured when
the reporter cell line was exposed to the light of 488/507nm at duration of image capture (Figure
9E).

(A)

(B)

(C)

(D)

22

(E)
Figure 9: Quantitative analysis of the distribution of
cytochrome C-GFP under apoptosis-inducing
reagents;
TRAIL
(100ng/ml,
400ng/ml),
Staurosporine (1µM), Tarceva (200nM), no drug
(control)

On the basis of this analysis, we monitored the release of cytochrome C-GFP expression
under confocal microscope when cells are treated with 400ng/ml TRAIL. Stack of images in the
z-direction were taken after two hours of giving the drug (Figure 9). Figure 10A, 10B shows the
middle of the cells where it was observed that GFP signal was completely diffused from the
mitochondria after two hours of treatment. The overlayed image shows the localization of GFP
and mitochondria after induction (Figure 10C). The Pearson’s correlation coefficient value was
Rp=0.45, which indicated that there were almost no co-localizations as observed of the data from
ch1 and ch2. (Figure 10D).

Figure 10: Colocalization of
cytochrome
C-GFP
with
mitochondria. All the images were
taken in 40X oil objective under
confocal
microscope.
(A)
Cytochrome C-GFP diffuse into
cytosol, (B) Cells were stained with
Mitoctracker for mitochondria, (C)
Overlay image of cytochrome CGFP
with
mitotracker
(D)
Quantitative
analysis
of
colocalization
image,
where
Rp=0.45

B

A

C
Red Channel

D
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4.5 Calibration of Microfluidic Duration Device
The fluid flow of Microfluidic Duration Device was calculated by stimulating different
flow rates. Microfluidic Duration device contains series of alternating parallel channels;
experimental channels and gap channels (Figure 11(i)). In order to deliver the right concentration
of any soluble stimuli, it is important to calibrate the flow rate by the number of experimental
channels receiving a certain flow. Therefore, two different food dyes were used in this
calibration: blue dye characterized a flow rate (QB) of basal culture medium that is delivered
through the left inlet and red dye characterized a flow rate of stimulus (Q

stimulus),

which will be

through the other inlet. Considering a low Reynolds number <100, we could minimize the
mixing of two solutions before entering into experimental channels. However, other factors may
influence the rate or occurrence of diffusion between two solution, therefore gap channels were
design between each experimental to carry the partially-mixed interface (Figure 11 (i), 11(ii)). By
using the flow rate at 10µl/min in left inlet and slowly increasing flow rate, starting from
0.1µl/min, at other inlet will cause fluid flow through the experimental channels without causing
diffusion. The result from the calibration graph shows that no red channels were filled at flow
rate of 0.1µl/min; however when flows rate increases to 1 µl/min three channels were filled
(Figure 11(iii). The result also verified that when red dye flow rate was lower, more experiment
channels were filled. As the flow rate increased, the number of experiment channels did not
change (Figure 11(iii)). Also, the profile of flow rate was not dependent on the time. For future
purposes, we can do drug screening and study the cellular response of cells by controlling the
flow rate with time and monitoring different period of drug stimulation.
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Right Inlet
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Outlet
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20
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Flow rate(ul/m im )
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6
4
2
0

n=0

Tim e

n=3n

n=4

n=7

n=8

n=9

n=10

n=11

n=12

n= number of experimental channels filled with red food dye
Figure 11: (i) AUTOCAD drawing of Microfludic Duration Device, (ii) Representation of Basal medium flow
rate of 10µl/min with blue food dye color, (iii) chart of flow rate with the number of experimental channels
filled.
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5. Discussion and Conclusion
In this present study, we used molecular biology techniques coupled with time lapse
fluorescence microscopy to investigate the release kinetics of cytochrome C-GFP in response to
three different apoptosis-inducing reagents; TRAIL, Staurosporine, and Tarceva. Previous studies
have shown that there are multiple mechanisms governing cytochrome C release into cytosol
simultaneously, but the choice of mechanism is dependent on the nature of apoptotic signal [25].
Investigators also found that cytochrome C-GFP release is early during apoptosis and leads
toward caspase activation [25, 26]. To study the release kinetics of cytochrome C in human lung
cancer cell (PC-9 cells), we have successfully developed a stable reporter cell line using GFP
tagged cytochrome C to monitor its release in response to different anti-cancer drugs. The
reporter cell line was characterized to confirm the existence and localization of cytochrome CGFP fusion proteins inside mitochondria before drug stimulation (Figure 3). The release of
cytochrome C GFP was monitored by time lapse imaging under fluorescence microscopy (Figure
7 (A-D)). In agreement with the investigators [27] our data also demonstrated that cytochrome
C-GFP was released after administration of apoptosis-inducing reagents and activates the
extrinsic or intrinsic pathway of apoptosis.
Initially, it was primary objective to characterize and confirm our constructed reporter
cell line. The results from western blot using anti-cytochrome C-GFP antibody and anti-EGFP
antibody confirmed two main purposes. First, it confirmed whether the expression of GFP
represents the intact cytochrome C-GFP fusion protein within the human lung cancer cell line
(PC-9). Second, results from western blotting helped to analyze the expression levels of fused
cytochrome C-GFP protein with the expression levels of endogenous cytochrome C present in
the reporter cell line. Our result showed that there were two distinguishable bands at
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different molecular weight that was exposed to anti-cytochrome C antibody, one between 89KDa
and 36KDa, and other below 18 KDa (Figure 6A). The band in between 89KDa & 36KDa
represented the cytochrome C-GFP fusion protein (~39KDa) and the below 18KDa one
corresponded to the molecular weight of the endogenous cytochrome C, typically around 12KDa.
This result demonstrated that the constructed reporter cells contain both cytochrome C- GFP
fusion protein and endogenous cytochrome C. Based on this result, we are confident that our
cytochrome C reporter cell line can be used to study the dynamic activities of endogenous
cytochrome C in response to an apoptosis-inducing reagent. These results agree with studies by
Goldstein et al., 2005 [27] and with the observations from the time lapse fluorescence images
(Figure 7 (A-D)). A protein band above 36 KDa was observed when anti-EGFP antibody was
used in the same western blot experiment. The band above 36KDa was expected to be
cytochrome C –GFP fusion protein (~ 39KDa). This result also confirmed that cytochrome CGFP was still fused together (Figure 6B). However, there were series of faint bands in between
39KDa and 31KDa which were expected due to the partial proteolytic cleavage of cytochrome
C-GFP. It was anticipated that an anti-EGFP antibody should depict a band at 27 KDa (the
molecular weight of GFP), however, no band showed up at this molecular weight. This result
concluded that there is no complete cleavage of GFP protein from the recombinant cytochrome
C-GFP.
The localization of cytochrome C-GFP was also confirmed by confocal microscopy with
MitoTracker. The overlay image of cytochrome C-GFP with mitotracker red fluorescent dye
confirmed the punctuated cytochrome C-GFP within mitochondria. Using ImageJ software, we
were able to generate a colocalization coefficient based on the fluorescence intensity of both
signals. It was determined that when the GFP signal was punctuated inside the
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mitochondria, the Pearson’s correlation coefficient (Rp) value was 0.772 (Figure 5C, 5D).
According to the statistic, when Rp = 1, it is a perfect colocalization; when Rp = 0, it is random;
and Rp = -1 represents perfect exclusion. Based on this value, the colocalization coefficient
between cytochrome C-GFP and MitoTracker dyed mitochondria in our reporter cells was closer
to 1 but not equal to one. When MitoTracker gets in the mitochondria, it reacts with thiols on
proteins and peptides to form an aldehyde-fixable conjugate (Invitrogen MitoTracker Manual).
Most likely MitoTracker shows off all protein locations in mitochondria but cytochrome c-GFP
only shows where cytochrome C proteins are.
We studied the release of cytochrome C from mitochondria in individual human lung
cancer cells. We found that the timing of cytochrome C release varies under different apoptosisinducing reagents. In this study, all the samples were prepared with identical experimental
conditions (e.g. cell seeding and fluorescence light exposure time). The results concluded that the
choice of apoptotic pathway (extrinsic or intrinsic) depends on the nature of apoptotic signal. The
result from the study of cytochrome C-GFP under the stimulation of rhTRAIL demonstrated that
different concentrations of rhTRAIL affect the release time of cytochrome C-GFP.

When

100ng/ml of rhTRAIL was introduced to the PC-9 reporter cell line, the diffusion of cytochrome
C-GFP was noticed between 2 and 3 hours time points (Figure 8A). Increase in the concentration
of rhTRAIL (400ng/ml) caused the release of cytochrome C-GFP between 0.5 and 1 hour (Figure
8B). Studies have shown that TRAIL in the human body binds with 5 distinct TRAIL receptors.
Two of them are DR4 and DR5 [28, 29]. The result from this study illustrated that a high
presence of pro-apoptotic ligand (TRAIL) caused more binding to the death receptors, eliciting
an earlier release of cytochrome C-GFP at the high TRAIL concentration.
We have found that staurosporine caused the release of cytochrome C-GFP
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between the time interval of 0.5 and 1 hour (Figure 8C), similar to release time of cytochrome CGFP when 400ng/ml TRAIL was induced. Preliminary studies have shown that staurosporine is
a promising anticancer agent that inhibits tumor cell growth by inducing cell death via intrinsic
apoptotic pathways [30, 31]. Based on our data result, we cannot conclude which pathway lead
to rapid induction of apoptosis. However, this result does confirm that the releasing time of
cytochrome C-GFP using in-vitro human model was different from the in-vitro animal model.
For rat pheochromocytoma-6 (PC-6) cell line, the release time of cytochrome C was noted after 2
hours [26]. From this study, we can determine that usage of an in-vitro animal model to study the
mechanism of apoptosis will not be as accurate as using an in-vitro human model, in particular to
drug screening.
Tarceva (Erlotnib). Erlotnib is most common anti-cancer drugs for non small cell lung
cancer. Studies have shown that Erlotnib inhibits tumor cell growth by binding with EGFR
(Epidermal Growth Factor) [32]. Investigator also found that erlotinib triggers apoptosis through
the intrinsic pathway [32, 33]. Previous studies have shown that induction of apoptosis by
erlotinib occurred in a dose and time-dependent manner [32]. We found that 200nM Tarceva
(erlotnib) invoked cytochrome C-GFP release after 1 hour (Figure 8D). According to study by
ling et al., 2008, the non small cell lung cancer treated with 0.1µM erlotinib releases cytochrome
C after 8 hours. Our result supported the statement that the induction of apoptosis does depend
on the dosage of erlotinib.
In addition, our results from the untreated (control) sample confirmed that the short-time
exposure of blue or green light from fluorescence microscopy itself does not trigger the releaseof
cytochrome C-GFP. From this result, we can conclude that majority of initiation of apoptosis was
due to the drug response.
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In order to confirm if there is a significant difference between the data from time point for
all three apoptosis-inducing reagents, we performed a two-tailed paired t-test with a confidence
interval of 95% (p<0.05) for CV (Coefficient of Variance) values across the releasing time. All
three treated groups had p< 0.05, depicting a significant change over time (CVs at 1 vs.1.5hrs for
Tarceva; CVs at 0.5 vs. 1hr for 400ng/ml TRAIL; CVs at 2 vs. 3hrs for 100ng/ml TRAIL and
CVs at 0.5 vs. 1hr for Staurosporine). For the control, there is no statistically significant
difference emerging over time within the control group using ANOVA (Analysis of Variance)
During the calibration of the microfluidic duration device, we demonstrated that a ratio of
100 between flow rates at two inlets would definitely allow cells in every channel expose to the
type of medium coming from the higher flow rate inlet. By reducing the ratio of flow rates
between two inlets, the number of micro-channels exposed to a desired stimulation can be
controlled. However, the upper limit of a flow rate is determinate by the shear stress cells can
tolerant. For example, a flow rate of 1µl/min gives us the shear stress value of 0.65dyne/cm2,
which is higher than the recommended limiting shear stress applied to the cell surface shear
stress (<0.1 dyne/cm2)[21]. This value of shear stress was calculated by the following equation:

zy =6Q/ wh2
(where Q is flow rate, is viscosity of the fluid, w and h are the channel width and height
respectively. zy is the stress felt by the cell if it were flat, since it corresponds to the main shear
forces exerted by the fluid). On the other hand, the lower limit of a flow rate is determined by
many factors from the limitation of a syringe pump and the lowest flow rate to avoid diffusion at
the interface of two media. In addition, it was also discovered that there are several factors
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that can increase the diffusion between two flows and affect the fluid flow, such as viscosity of
fluid and bubble formation. Therefore, it is important to consider these scenarios before
conducting the experiment. The flow rates used in current study may be too high. Further
calibration experiments need to be done to find an optimized pair to satisfy two conditions,
minimum shear stress and minimum fluid mixing at the interface.
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6. Summary and Future Studies
A cytochrome C-GFP reporter cell line was successfully constructed using human lung
cancer cells. The fusion status of cytochrome C-GFP and its localization in mitochondria was
confirmed in the reporter cell line. In addition, the release kinetics of cytochrome C-GFP in
response to three different apoptosis-inducing reagents, TRAIL, Staurosporine, and Tarceva,
were studied to demonstrate the application of this reporter cell line in the area of anti-cancer
drug discovery and screening targeting apoptosis pathways. The result from this study illustrated
that the dynamic release of cytochrome C-GFP is dependent on the cell types and doses.
The cytochrome c-GFP reporter cell line can be further used to test the natural
compounds and its potential to trigger apoptosis. The results from this study can be used as a
control to investigate the apoptosis-inducing ability in the signaling pathways by natural
compounds that are currently in research, e.g. Actein [35]. It will be interesting to know, which
pathways of apoptosis Actein may lead to. According to our result, different concentrations of
rhTRAIL give different release times of cytochrome C-GFP (400 ng/ml rhTRAIL release
cytochrome C-GFP after 0.5 hrs, which was the similar release time when the cells were exposed
to Staurosporine). As mentioned before, these two apoptosis-inducing reagents initiates apoptosis
in two different signaling pathways (extrinsic and intrinsic). Using an earlier detection of
apoptosis staining dye, Annexin-V, we can monitor which reagent lead to apoptosis faster or
whether rhTRAIL induces apoptosis associated with the activation of caspases in a dose- and
time-dependent manner as Tarceva.
We have also calibrated a microfluidic duration device to investigate the anti-cancer
drugs response at different duration. In the future, this system can be used to monitor/investigate
the synergistic drug response in time-series that may be concurrently utilized for more
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effective cancer treatments. For instance, preliminary data from the combination of bevacizumab
and erlotinib suggest that it may provide benefit in a broader population of NSCLC (none small
cell lung cancer) than each agent individually [34].

Using our reporter cell line in our

microfluidic duration device we can study the synergistic effects of these two anti-cancer
reagents (e.g. what is the optimized time interval between applying two drugs in order to reach a
maximum therapeutic effects). As a result, our system can facilitate the development of improved
target therapy for NSCLC by suggesting different implementations of drugs.
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